Under construction – not a live service

Skip to content

Frontlight Research

Institution

Fundación Valle del Lili

Cali, ColombiaWebsite

42running trials
19closed trials
3,783publications (OpenAlex)

Running trials

Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613· Phase 3· Novo Nordisk A/S· Source
Recruiting
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
NCT07539844· AbbVie· Source
Active, not recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
NCT07463183· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT07363590· Phase 1· Merck Sharp & Dohme LLC· Source
Not yet recruiting
Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.
NCT06875791· Phase 1/2· Fundacion Clinica Valle del Lili· Source
Active, not recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077· Phase 2/3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
NCT07044297· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Active, not recruiting
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012· Phase 2· Takeda· Source
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Recruiting
Relationship Between Pulse Pressure and Stroke Volume in the Critically Ill Patients: The ANDROMEDA-PEGASUS Study
NCT06737614· Pontificia Universidad Catolica de Chile· Source
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Enrolling by invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115· Indiana University· Source
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
NCT05587049· AbbVie· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT05947851· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085· Phase 2/3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
NCT05766501· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500· Phase 3· Viatris Innovation GmbH· Source
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017· Phase 2/3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877· Phase 3· Merck Sharp & Dohme LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
NCT05952856· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
American Registry of Ambulatory or Acutely Decompensated Heart Failure
NCT05295641· Fundacion Clinica Valle del Lili· Source
Completed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
Cardiovascular Registry of Atrial Fibrillation
NCT04456842· Brazilian Clinical Research Institute· Source
Completed
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
NCT04305054· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
NCT04233879· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
NCT04223778· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326· Phase 3· Novo Nordisk A/S· Source
Completed
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT03797326· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449· Phase 3· Eisai Inc.· Source
Completed
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223· Phase 3· CSL Behring· Source
Completed
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
NCT03283085· Phase 3· Shire· Source
Completed
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
NCT03040999· Phase 3· Merck Sharp & Dohme LLC· Source

Registry name variants (45)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Fundación Valle del Lili
Cali, Valle del Cauca Department 760032
14 trials
Fundación Valle de Lili
Cali, 760032
2 trials
- NCT05686070A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
- NCT05648500A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Fundacion Valle del Lili (Site 0403)
Cali, Valle del Cauca Department 760032
2 trials
- NCT07058077A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
  Contact: Study Coordinator
- NCT06956235Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Fundación Valle del Lili (Site 0904)
Cali, Valle del Cauca Department 760032
2 trials
- NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- NCT05952856A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
1700011 - Fundación Valle del Lili
Cali, 760032
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Fundacion Valle del Lili Cali
Cali
1 trial
- NCT06823115Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Fundación Valle del Lili-Fundacion Valle del Lili (Site 0607)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Fundacion Valle Del Lili /ID# 248294
Cali, Valle del Cauca Department 760016
1 trial
- NCT05587049A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
  Contact: Angela Duarte
Fundacion Valle Del Lili /ID# 280794
Cali, Valle del Cauca Department 760016
1 trial
- NCT07539844Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
  Contact: Rebekah Taylor
Fundacion Valle del Lili (Site 0102)
Cali, Valle del Cauca Department 760032
1 trial
- NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
  Contact: Study Coordinator
Fundacion Valle del Lili (Site 0140)
Cali, Valle del Cauca Department 760032
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Fundacion Valle del Lili (Site 0150)
Cali, Valle del Cauca Department 760032
1 trial
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Fundación Valle del Lili (Site 0200)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05587712Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
  Contact: Study Coordinator
Fundacion Valle del Lili (Site 0230)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Fundación Valle del Lili (Site 0330)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  Contact: Study Coordinator
Fundación Valle del Lili (Site 0402)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06465186A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Fundación Valle del Lili (Site 0406)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Fundación Valle del Lili (Site 0412)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06113328A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Fundación Valle del Lili (Site 0502)
Cali, Valle del Cauca Department 760032
1 trial
- NCT07044297A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Fundación Valle del Lili (Site 0505)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  Contact: Study Coordinator
Fundación Valle del Lili (Site 0508)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Study Coordinator
Fundación Valle del Lili (Site 0509)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Fundación Valle del Lili (Site 0602)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Contact: Study Coordinator
Fundación Valle del Lili (Site 0604)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  Contact: Study Coordinator
Fundación Valle del Lili (Site 0700)
Cali, Valle del Cauca Department 760026
1 trial
- NCT05877547A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Fundacion Valle del Lili (Site 0802)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
  Contact: Toll Free Number
Fundación Valle del Lili (Site 0903)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Fundación Valle del Lili (Site 1093)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Fundacion Valle del Lili (Site 1101)
Cali, Valle del Cauca Department 760032
1 trial
- NCT03797326Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Fundación Valle del Lili (Site 1162)
Cali, Valle del Cauca Department 760032
1 trial
- NCT07463183A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
  Contact: Study Coordinator
Fundacion Valle del Lili (Site 1201)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04223778Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
Fundacion Valle del Lili (Site 1204)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06428396Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Fundación Valle del Lili (Site 1305)
Cali, Valle del Cauca Department 760032
1 trial
- NCT07176390A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Fundación Valle del Lili (Site 1500)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05766501A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
Fundación Valle del Lili (Site 1656)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04700124Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Fundación Valle del Lili (Site 1703)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05947851A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
  Contact: Study Coordinator
Fundación Valle del Lili (Site 1901)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Fundación Valle del Lili (Site 2201)
Cali, Valle del Cauca Department 760032
1 trial
- NCT07133633A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Fundación Valle del Lili (Site 2265)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04305054Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Fundación Valle del Lili (Site 2307)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Fundación Valle del Lili (Site 2505)
Cali, Valle del Cauca Department 760032
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Fundación Valle del Lili (Site 2704)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  Contact: Study Coordinator
Fundacion Valle del Lili (Site 6001)
Cali, Valle del Cauca Department 760032
1 trial
- NCT04233879Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Fundación Valle del Lili (Site 6308)
Cali, Valle del Cauca Department 760032
1 trial
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
Fundación Valle del Lili (Site 8302)
Cali, Valle del Cauca Department 760032
1 trial
- NCT07486960Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Conditions

Diseases this institution publishes on or runs trials for.

High blood pressure6 works · 4 trials

Institution data: ROR 00xdnjz02 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Fundación Valle del Lili: trials and research groups – Frontlight Research